Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/157307
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Martínez Yélamos, Antonio | - |
dc.contributor.author | Saiz Hinarejos, Albert | - |
dc.contributor.author | Sánchez del Valle Díaz, Raquel | - |
dc.contributor.author | Casado Ruiz, Virginia | - |
dc.contributor.author | Ramon Torrell, Josep M. (Josep Maria) | - |
dc.contributor.author | Graus Ribas, Francesc | - |
dc.contributor.author | Arbizu Urdiain, Txomin | - |
dc.date.accessioned | 2020-04-24T11:17:43Z | - |
dc.date.available | 2020-04-24T11:17:43Z | - |
dc.date.issued | 2001-08-28 | - |
dc.identifier.issn | 0028-3878 | - |
dc.identifier.uri | http://hdl.handle.net/2445/157307 | - |
dc.description.abstract | Axonal damage probably occurs early in the evolution of MS. Five of 38 (13%) patients had a positive assay for the neuronal 14-3-3 protein in the CSF obtained at the first clinically isolated syndrome suggestive of MS. A positive 14-3-3 assay was the only independent predictor for a shorter time to conversion to clinical definite MS (risk ratio 4.1; 95% CI 1.1 to 15) and to reach an Expanded Disability Status Scale (EDSS) > or =2 at the end of follow-up (odds ratio 14.8; 95% CI 2.86 to 76.8). The detection of the 14-3-3 protein in the CSF at the first neurologic event suggestive of MS may be a useful predictor of short-term evolution. | - |
dc.format.extent | 3 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Lippincott, Williams & Wilkins. Wolters Kluwer Health | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1212/wnl.57.4.722 | - |
dc.relation.ispartof | Neurology, 2001, vol. 57, num. 4, p. 722-724 | - |
dc.relation.uri | https://doi.org/10.1212/wnl.57.4.722 | - |
dc.rights | (c) American Academy of Neurology, 2001 | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Líquid cefalorraquidi | - |
dc.subject.classification | Esclerosi múltiple | - |
dc.subject.classification | Proteïna-tirosina-fosfatasa | - |
dc.subject.other | Cerebrospinal fluid | - |
dc.subject.other | Multiple sclerosis | - |
dc.subject.other | Protein-tyrosine phosphatase | - |
dc.title | 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 500870 | - |
dc.date.updated | 2020-04-24T11:17:43Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 11524491 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
500870.pdf | 57.3 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.